174 related articles for article (PubMed ID: 24875819)
21. Clinical and oncologic findings of extraprostatic extension on needle biopsy in
Chen JR; Zhao JG; Zhu S; Zhang MN; Chen N; Liu JD; Sun GX; Shen PF; Zeng H
Asian J Androl; 2020; 22(4):427-431. PubMed ID: 31424026
[TBL] [Abstract][Full Text] [Related]
22. Progesterone receptor expression during prostate cancer progression suggests a role of this receptor in stromal cell differentiation.
Yu Y; Yang O; Fazli L; Rennie PS; Gleave ME; Dong X
Prostate; 2015 Jul; 75(10):1043-50. PubMed ID: 25833156
[TBL] [Abstract][Full Text] [Related]
23. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
24. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
25. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
26. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
27. Gray level entropy matrix is a superior predictor than multiplex ELISA in the detection of reactive stroma and metastatic potential of high-grade prostatic adenocarcinoma.
Jia X; Sun Y; Wang B
IUBMB Life; 2014 Dec; 66(12):847-53. PubMed ID: 25631296
[TBL] [Abstract][Full Text] [Related]
28. Metalloproteinase 11, potential marker and molecular target in advanced and castration-resistant prostate cancer. Culture study of peritumoral fibroblasts.
Fernandez-Gomez JM; Eiro N; García-Rodríguez JJ; Quintás-Blanco A; Gonzalez-Ruiz de León C; Perez de Haro ML; Vizoso-Piñero F
Actas Urol Esp; 2017; 41(6):376-382. PubMed ID: 28161070
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of normal stromal components and their correlation with cancer occurrence in human prostate.
Zhang Y; Nojima S; Nakayama H; Jin Y; Enza H
Oncol Rep; 2003; 10(1):207-11. PubMed ID: 12469170
[TBL] [Abstract][Full Text] [Related]
30. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia.
Schauer IG; Ressler SJ; Tuxhorn JA; Dang TD; Rowley DR
Urology; 2008 Jul; 72(1):205-13. PubMed ID: 18314176
[TBL] [Abstract][Full Text] [Related]
31. Combining lymphovascular invasion with reactive stromal grade predicts prostate cancer mortality.
Saeter T; Vlatkovic L; Waaler G; Servoll E; Nesland JM; Axcrona K; Axcrona U
Prostate; 2016 Sep; 76(12):1088-94. PubMed ID: 27271973
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of both tumor and stromal expression of components of the IL-1 and TNF-α signaling pathways in prostate cancer.
Rodríguez-Berriguete G; Sánchez-Espiridión B; Cansino JR; Olmedilla G; Martínez-Onsurbe P; Sánchez-Chapado M; Paniagua R; Fraile B; Royuela M
Cytokine; 2013 Nov; 64(2):555-63. PubMed ID: 24063999
[TBL] [Abstract][Full Text] [Related]
33. High stroma-derived WNT5A is an indicator for low-risk prostate cancer.
Kisel W; Conrad S; Borkowetz A; Furesi G; Füssel S; Sommer U; Rauner M; Thomas C; Baretton GB; Schaser KD; Hofbauer C; Hofbauer LC
FEBS Open Bio; 2021 Apr; 11(4):1186-1194. PubMed ID: 33639039
[TBL] [Abstract][Full Text] [Related]
34. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer.
Ryan CJ; Haqq CM; Simko J; Nonaka DF; Chan JM; Weinberg V; Small EJ; Goldfine ID
Urol Oncol; 2007; 25(2):134-40. PubMed ID: 17349528
[TBL] [Abstract][Full Text] [Related]
35. Expression of store-operated channel components in prostate cancer: the prognostic paradox.
Perrouin Verbe MA; Bruyere F; Rozet F; Vandier C; Fromont G
Hum Pathol; 2016 Mar; 49():77-82. PubMed ID: 26826413
[TBL] [Abstract][Full Text] [Related]
36. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of periostin in stroma positively associated with aggressive prostate cancer.
Tian Y; Choi CH; Li QK; Rahmatpanah FB; Chen X; Kim SR; Veltri R; Chia D; Zhang Z; Mercola D; Zhang H
PLoS One; 2015; 10(3):e0121502. PubMed ID: 25781169
[TBL] [Abstract][Full Text] [Related]
38. Modulating tumor reactive stroma by extracorporeal shock waves to control prostate cancer progression.
Rinella L; Pizzo B; Frairia R; Delsedime L; Calleris G; Gontero P; Zunino V; Fortunati N; Arvat E; Catalano MG
Prostate; 2020 Sep; 80(13):1087-1096. PubMed ID: 32609927
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome.
Josefsson A; Adamo H; Hammarsten P; Granfors T; Stattin P; Egevad L; Laurent AE; Wikström P; Bergh A
Am J Pathol; 2011 Oct; 179(4):1961-8. PubMed ID: 21854754
[TBL] [Abstract][Full Text] [Related]
40. Predicting factors for progression to castration resistance prostate cancer after biochemical recurrence in patients with clinically localized prostate cancer who underwent radical prostatectomy.
Hashimoto T; Nakashima J; Kashima T; Yamaguchi Y; Satake N; Nakagami Y; Namiki K; Ohno Y
Int J Clin Oncol; 2020 Sep; 25(9):1704-1710. PubMed ID: 32500468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
